✦ LIBER ✦

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

✍ Scribed by Ludwig Kappos; Ralf Gold; David H Miller; David G MacManus; Eva Havrdova; Volker Limmroth; Chris H Polman; Klaus Schmierer; Tarek A Yousry; Minhua Yang; Mefkûre Eraksoy; Eva Meluzinova; Ivan Rektor; Katherine T Dawson; Alfred W Sandrock; Gilmore N O'Neill

Book ID: 117303824
Publisher: The Lancet
Year: 2008
Tongue: English
Weight: 209 KB
Volume: 372
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(08)61619-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effect of laquinimod on MRI-monitored di

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

✍ G Comi; A Pulizzi; M Rovaris; O Abramsky; T Arbizu; A Boiko; R Gold; E Havrdova; 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 143 KB

Randomised double-blind placebo-controll

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

✍ George C Ebers 📂 Article 📅 1998 🏛 The Lancet 🌐 English ⚖ 97 KB

Methylprednisolone in combination with i

Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial

✍ Mads Ravnborg; Per Soelberg Sørensen; Magnus Andersson; Elisabeth G Celius; Pete 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 374 KB

Effects of oral glatiramer acetate on cl

Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study

✍ Massimo Filippi; Jerry S Wolinsky; Giancarlo Comi 📂 Article 📅 2006 🏛 The Lancet 🌐 English ⚖ 185 KB

Repeated subcutaneous injections of IL12

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

✍ Benjamin M Segal; Cris S Constantinescu; Aparna Raychaudhuri; Lilianne Kim; Rosa 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 180 KB

Daclizumab in active relapsing multiple

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

✍ Daniel Wynn; Michael Kaufman; Xavier Montalban; Timothy Vollmer; Jack Simon; Jac 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 456 KB